MBRX Announces Acceptance of Annamycin Cardiac Safety Data Abstract for Poster Presentation at 2026 ASCO Annual Meeting, Highlights No Statistically Significant Change in LVEF, No Evidence of Drug-Induced Cardiotoxicity
Moleculin Biotech, Inc. · PHARMACEUTICAL PREPARATIONS · Now $2.79
+15% in 3d after detection
Post-detection moves
1h
-0.4%
1d
+2.1%
3d
+15%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS